Trial Profile
Open-label pharmacokinetics study of abt-493 and abt-530 given in combination in healthy adult subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2017
Price :
$35
*
At a glance
- Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 07 Aug 2015 New trial record